Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Immunotherapy has produced durable clinical benefit in patients with metastatic renal cell cancer (RCC). In the past, patients treated with interferon-alpha (IFN) and interleukin-2 (IL-2) have achieved complete responses, many of which have lasted for multiple decades. More recently, a large number...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunother Cancer
Hauptverfasser: Rini, Brian I., McDermott, David F., Hammers, Hans, Bro, William, Bukowski, Ronald M., Faba, Bernard, Faba, Jo, Figlin, Robert A., Hutson, Thomas, Jonasch, Eric, Joseph, Richard W., Leibovich, Bradley C., Olencki, Thomas, Pantuck, Allan J., Quinn, David I., Seery, Virginia, Voss, Martin H., Wood, Christopher G., Wood, Laura S., Atkins, Michael B.
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2016
Schlagworte:
Position Article and Guidelines
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5109802/
https://ncbi.nlm.nih.gov/pubmed/27891227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-016-0180-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge